Payment overview · 2025
General Payments
$745.12
33 reported records · 13 companies
Healthcare provider profile · identity verified
Mark Gelfand, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1801849658
Verified facts
What the public records show
CMS Open Payments records show Mark Gelfand, MD received $745.12 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Edarbi, Eliquis, Farxiga, Horizant, Linzess, Mounjaro, Ozempic, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 423 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nexium by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Edarbyclor by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Horizant by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 480 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.38 | 20.1% | 8 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.55 | 16.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.49 | 12.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $61.30 | 8.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.14 | 7.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.65 | 6.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.64 | 5.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.00 | 5.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.85 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.53 | 3.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.25 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.51 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.83 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.12 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $96.49 | 4 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $83.85 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.08 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $61.30 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.14 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.56 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $46.56 | 3 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $26.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 97 | exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 480 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| HORIZANT horizant |
2025 | Horizant | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 169 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
97 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
169 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
423 | 52 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
480 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1303 | 198 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1085 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 989 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 839 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 93 |
| Losartan Potassium | Losartan Potassium | 659 | 104 |
| Omeprazole | Omeprazole | 536 | 93 |
| Metformin Hcl | Metformin Hcl | 522 | 84 |
| Eliquis | Apixaban | 480 | 68 |
| Synthroid | Levothyroxine Sodium | 423 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 385 | 57 |
| Carvedilol | Carvedilol | 355 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 349 | 51 |
| Ezetimibe | Ezetimibe | 336 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 44 |
| Famotidine | Famotidine | 275 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 269 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 264 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 39 |
| Doxazosin Mesylate | Doxazosin Mesylate | 245 | 37 |
| Vascepa | Icosapent Ethyl | 243 | 39 |
| Allopurinol | Allopurinol | 231 | 37 |
| Simvastatin | Simvastatin | 231 | 35 |
| Memantine Hcl Er | Memantine Hcl | 220 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 49 |
| Januvia | Sitagliptin Phosphate | 200 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 198 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 193 | 71 |
| Hydralazine Hcl | Hydralazine Hcl | 193 | 28 |
| Alendronate Sodium | Alendronate Sodium | 190 | 22 |
| Linzess | Linaclotide | 169 | 32 |
| Lisinopril | Lisinopril | 169 | 20 |
| Valsartan | Valsartan | 159 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 157 | 25 |
| Furosemide | Furosemide | 156 | 28 |
| Memantine Hcl | Memantine Hcl | 155 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 23 |
| Glipizide Er | Glipizide | 147 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 33 |
| Tradjenta | Linagliptin | 144 | 16 |
| Enalapril Maleate | Enalapril Maleate | 142 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 66 |
| Donepezil Hcl | Donepezil Hcl | 139 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 44 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 135 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 16 |
| Gabapentin | Gabapentin | 130 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 121 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 119 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 119 | 21 |
| Telmisartan | Telmisartan | 119 | 19 |
| Metformin Hcl Er | Metformin Hcl | 112 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 104 | 24 |
| Atenolol | Atenolol | 103 | 13 |
| Glimepiride | Glimepiride | 98 | 12 |
| Creon | Lipase/Protease/Amylase | 97 | 23 |
| Zenpep | Lipase/Protease/Amylase | 97 | 22 |
| Mirtazapine | Mirtazapine | 80 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 63 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 76 | 12 |
| Dutasteride | Dutasteride | 73 | 11 |
| Edarbi | Azilsartan Medoxomil | 72 | suppressed |
| Lidocaine | Lidocaine | 70 | 17 |
| Meloxicam | Meloxicam | 70 | 46 |
| Clonidine Hcl | Clonidine Hcl | 69 | 28 |
| Ramipril | Ramipril | 69 | 11 |
| Azithromycin | Azithromycin | 68 | 55 |
| Jardiance | Empagliflozin | 68 | 11 |
| Meclizine Hcl | Meclizine Hcl | 65 | 33 |
| Torsemide | Torsemide | 64 | 12 |
| Dexilant | Dexlansoprazole | 62 | 11 |
| Montelukast Sodium | Montelukast Sodium | 62 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 62 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | suppressed |
| Repaglinide | Repaglinide | 57 | suppressed |
| Glipizide | Glipizide | 56 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 55 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Potassium Chloride | Potassium Chloride | 53 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 50 | 15 |
| Cefuroxime | Cefuroxime Axetil | 50 | 41 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | 11 |
| Myrbetriq | Mirabegron | 45 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 18 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | suppressed |
| Febuxostat | Febuxostat | 42 | suppressed |
| Livalo | Pitavastatin Calcium | 42 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 41 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 26 |
| Single Use Swab | Alcohol Antiseptic Pads | 41 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Felodipine Er | Felodipine | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 14 |
| Ozempic | Semaglutide | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 36 | 21 |
| Cilostazol | Cilostazol | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Lorazepam | Lorazepam | 35 | 14 |
| Mupirocin | Mupirocin | 35 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 17 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Nexium | Esomeprazole Magnesium | 32 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 26 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 28 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 27 |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Bystolic | Nebivolol Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Mometasone Furoate | Mometasone Furoate | 24 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Uloric | Febuxostat | 22 | suppressed |
| Acarbose | Acarbose | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Crestor | Rosuvastatin Calcium | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 14 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Prolia | Denosumab | 20 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 11 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Ambien | Zolpidem Tartrate | 13 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Disopyramide Phosphate | Disopyramide Phosphate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Rapaflo | Silodosin | 13 | suppressed |
| Repatha Pushtronex | Evolocumab | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Zetia | Ezetimibe | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.12 · 33 records | ABBVIE INC. | BREZTRI, CREON, EDARBI, ELIQUIS, EVENITY, FARXIGA, HORIZANT, IBSRELA, Kerendia, LAGEVRIO, LINZESS, MAVYRET, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PROLIA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error